Wagner Britta Janina, Plum Patrick Sven, Apel Katharina, Scherer Marie, Buchner Denise, Brinkmann Sebastian, Buettner Reinhard, Stippel Dirk, Quaas Alexander, Drebber Uta
Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, D-50937 Cologne, Germany.
Department of General, Visceral, Cancer and Transplant Surgery, University of Cologne, Faculty of Medicine and University Hospital Cologne, D-50937 Cologne, Germany.
Oncol Lett. 2021 May;21(5):349. doi: 10.3892/ol.2021.12610. Epub 2021 Mar 3.
Cholangiocarcinoma (CCA) is an aggressive malignancy with a 5-year-survival rate of <10%, mainly due to diagnosis in advanced stages and limited therapeutic options in case of progressive disease. Recently, evidence has indicated that alterations in the SWI/SNF-complex (SWI/SNF) may have an important role in the tumorigenesis of CCA. SWI/SNF-related chromatin remodeling has been reported to be crucial for differentiation and tumor suppression, and loss-of-function mutations of SWI/SNF are present in 20% of human malignancies; however, at present, little is known about its relevance in CCA. In the present study, a cohort of 52 patients with the diagnosis of primary CCA was retrospectively collected. All patients underwent surgery with curative intent. Tissue microarray analysis was performed on each tumor for immunohistochemical loss-of-protein analysis of the SWI/SNF core subunits ARID1A, INI-1, BRG1, PBRM-1 and BRM, corresponding to the following CCA subtypes: Extrahepatic CCA (ECCA), small duct or large duct intrahepatic CCA (ICCA). Kaplan-Meier analysis was used to determine survival distribution and survival differences were evaluated by log-rank test. In total, 14 of 52 patients (~35%) exhibited protein-loss of any tested SWI/SNF core subunit. Notably, 17% of patients exhibited a loss of ARID1a; this was the protein loss with the highest frequency. Patients with small and large duct ICCA with protein-loss of any tested SWI/SNF subunit exhibited significantly worse survival compared with the wild-type cohort with proficient protein expression (P=0.013 and P=0.002), whereas no significant survival difference was detected for patients with ECCA. SWI/SNF and its core subunits may be considered promising predictive and therapeutic targets, and require further investigation in patients with CCA.
胆管癌(CCA)是一种侵袭性恶性肿瘤,5年生存率<10%,主要原因是其常在晚期才被诊断出来,且疾病进展时治疗选择有限。最近,有证据表明,SWI/SNF复合物(SWI/SNF)的改变可能在CCA的肿瘤发生中起重要作用。据报道,SWI/SNF相关的染色质重塑对于细胞分化和肿瘤抑制至关重要,并且SWI/SNF的功能丧失突变存在于20%的人类恶性肿瘤中;然而,目前对其在CCA中的相关性知之甚少。在本研究中,回顾性收集了52例诊断为原发性CCA的患者队列。所有患者均接受了根治性手术。对每个肿瘤进行组织微阵列分析,以对SWI/SNF核心亚基ARID1A、INI-1、BRG1、PBRM-1和BRM进行免疫组化蛋白缺失分析,这些亚基对应于以下CCA亚型:肝外CCA(ECCA)、小胆管或大胆管肝内CCA(ICCA)。采用Kaplan-Meier分析确定生存分布,并通过对数秩检验评估生存差异。总共52例患者中有14例(约35%)表现出任何测试的SWI/SNF核心亚基的蛋白缺失。值得注意的是,17%的患者表现出ARID1a缺失;这是频率最高的蛋白缺失。任何测试的SWI/SNF亚基蛋白缺失的小胆管和大胆管ICCA患者与蛋白表达正常的野生型队列相比,生存率显著更差(P=0.013和P=0.002),而ECCA患者未检测到显著的生存差异。SWI/SNF及其核心亚基可能被认为是有前景的预测和治疗靶点,需要在CCA患者中进一步研究。